“Ulcerative Colitis Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ulcerative Colitis Market.

The Ulcerative Colitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Ulcerative Colitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Ulcerative Colitis treatment therapies with a considerable amount of success over the years.

• Ulcerative Colitis companies working in the treatment market are NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others, are developing therapies for the Ulcerative Colitis treatment

• Emerging Ulcerative Colitis therapies in the different phases of clinical trials are- MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others are expected to have a significant impact on the Ulcerative Colitis market in the coming years.

• In July 2025, Abivax SA has reported favorable topline results from its Phase 3 induction trials, ABTECT-1 (Study 105) and ABTECT-2 (Study 106), assessing obefazimod (ABX464) in adult patients with moderate to severe ulcerative colitis (UC) over an 8-week treatment period.

• In February 2025, Johnson & Johnson’s (J&J) fully subcutaneous formulation of Tremfya (guselkumab) has delivered a second positive outcome in ulcerative colitis (UC), with 27.6% of participants achieving clinical remission in a Phase III trial. The randomized, double-blind Phase III Astro trial (NCT05528510) evaluated the subcutaneous injectable form of Tremfya for both induction and maintenance treatment in 418 adults with moderate to severe UC, an inflammatory bowel disease (IBD), who had previously shown an inadequate response to standard therapies.

• In February 2025, Iterative Health, a healthcare technology and services company focused on enhancing gastrointestinal care in collaboration with physicians, is set to present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, from February 19–22, 2025. The presentations will highlight the exceptional performance of the company’s AI-enabled Endoscopic Score (AI-ES) and its extended version (AI-ESe) in delivering standardized, reproducible assessments of disease severity and treatment response in ulcerative colitis (UC). These findings were developed in partnership with Eli Lilly and Company and leading academic experts.

• In February 2025, Teva and Sanofi have released new findings from the Phase IIb RELIEVE UCCD trial assessing duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody that targets TL1A, for treating moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD). The updated data were presented at the 20th Congress of the European Crohn’s and Colitis Organization (ECCO) held in Berlin, Germany.

Ulcerative Colitis Overview

Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by inflammation and ulcers in the lining of the colon and rectum. It is believed to be caused by an abnormal immune response in which the body’s immune system mistakenly attacks healthy tissues in the gastrointestinal tract.

Get a Free Sample PDF Report to know more about Ulcerative Colitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/ulcerative-colitis-uc-pipeline-insight

Emerging Ulcerative Colitis Drugs Under Different Phases of Clinical Development Include:

• PRA023: Prometheus Biosciences

• OSE-127: OSE Immunotherapeutics

• Brazikumab: AstraZeneca

• MORF-057: Morphic Therapeutic

• Risankizumab: AbbVie

• Cobitolimod: InDex Pharmaceuticals

• Etrasimod: Pfizer

• PL8177: Palatin Technologies, Inc

• Mirikizumab: Eli Lilly and Company

• Guselkumab: Janssen Research & Development, LLC

• Efavaleukin alfa: Amgen

• NX-13: Landos Biopharma Inc.

• Remestemcel-L: Mesoblast, Inc.

• Ozanimod: Bristol-Myers Squibb

• ABX464: Abivax S.A.

• VTX002: Oppilan Pharma Ltd

• AJM300: EA Pharma Co., Ltd.

• PRA023 IV: Prometheus Biosciences, Inc.

• SAR443122: Sanofi

• GLPG3970: Galapagos NV

• Ozanimod: Celgene

Ulcerative Colitis Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Ulcerative Colitis Molecule Type

Ulcerative Colitis Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Ulcerative Colitis Pipeline Therapeutics Assessment

• Ulcerative Colitis Assessment by Product Type

• Ulcerative Colitis By Stage and Product Type

• Ulcerative Colitis Assessment by Route of Administration

• Ulcerative Colitis By Stage and Route of Administration

• Ulcerative Colitis Assessment by Molecule Type

• Ulcerative Colitis by Stage and Molecule Type

DelveInsight’s Ulcerative Colitis Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Ulcerative Colitis product details are provided in the report. Download the Ulcerative Colitis pipeline report to learn more about the emerging Ulcerative Colitis therapies

Some of the key companies in the Ulcerative Colitis Therapeutics Market include:

Key companies developing therapies for Ulcerative Colitis are – Merck & Co., Inc.,, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Eli Lilly and Company, AbbVie Inc. (Allergan, Inc.), Bausch Health Companies Inc., Johnson and Johnson, Novartis AG, Bristol Myers Squibb, Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., and others.

Ulcerative Colitis Pipeline Analysis:

The Ulcerative Colitis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment.

• Ulcerative Colitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Ulcerative Colitis drugs and therapies

Ulcerative Colitis Pipeline Market Drivers

• Increasing awareness and R&D investment, emergence of large number of novel pipeline molecules with great market potential are some of the important factors that are fueling the Ulcerative Colitis Market.

Ulcerative Colitis Pipeline Market Barriers

• However, side effects associated with the treatment, high cost treatment and other factors are creating obstacles in the Ulcerative Colitis Market growth.

Scope of Ulcerative Colitis Pipeline Drug Insight

• Coverage: Global

• Key Ulcerative Colitis Companies: NuBiyota, Adiso Therapeutics, Landos Biopharma, Prometheus Biosciences, OSE Immunotherapeutics, AstraZeneca, Morphic Therapeutic, AbbVie, InDex Pharmaceuticals, Pfizer, Palatin Technologies, Inc, Eli Lilly and Company, Janssen Research & Development, LLC, Amgen, Landos Biopharma Inc., Mesoblast, Inc., Bristol-Myers Squibb, Abivax S.A., Oppilan Pharma Ltd, EA Pharma Co., Ltd., Prometheus Biosciences, Inc., Sanofi, Galapagos NV, Celgene, and others

• Key Ulcerative Colitis Therapies: MET-2, BT051, NX-13, PRA023, OSE-127, Brazikumab, MORF-057, Risankizumab, Cobitolimod, Etrasimod, PL8177, Mirikizumab, Guselkumab, Efavaleukin alfa, NX-13, Remestemcel-L, Ozanimod, ABX464, VTX002, AJM300, PRA023 IV, SAR443122, GLPG3970, Ozanimod, and others

• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies

• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers

Request for Sample PDF Report for Ulcerative Colitis Pipeline Assessment and clinical trials

Table of Contents

1. Ulcerative Colitis Report Introduction

2. Ulcerative Colitis Executive Summary

3. Ulcerative Colitis Overview

4. Ulcerative Colitis- Analytical Perspective In-depth Commercial Assessment

5. Ulcerative Colitis Pipeline Therapeutics

6. Ulcerative Colitis Late Stage Products (Phase II/III)

7. Ulcerative Colitis Mid Stage Products (Phase II)

8. Ulcerative Colitis Early Stage Products (Phase I)

9. Ulcerative Colitis Preclinical Stage Products

10. Ulcerative Colitis Therapeutics Assessment

11. Ulcerative Colitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Ulcerative Colitis Key Companies

14. Ulcerative Colitis Key Products

15. Ulcerative Colitis Unmet Needs

16 . Ulcerative Colitis Market Drivers and Barriers

17. Ulcerative Colitis Future Perspectives and Conclusion

18. Ulcerative Colitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/